atrasentan has been researched along with Disease Models, Animal in 55 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (7.27) | 18.2507 |
| 2000's | 27 (49.09) | 29.6817 |
| 2010's | 20 (36.36) | 24.3611 |
| 2020's | 4 (7.27) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Abdelhady, SA; Darwish, IE; El-Deeb, NM; El-Mas, MM; Gowayed, MA; Habib, YH | 1 |
| Bądzyńska, B; Hojná, S; Kompanowska-Jezierska, E; Sadowski, J; Vaneckova, I | 1 |
| Alpers, CE; Hudkins, KL; Steegh, F; Wietecha, TA | 1 |
| Bowles, T; Gibbens, J; Morris, R; Spencer, SK; Wallace, K | 1 |
| Andress, D; Becker, K; Johnson, AC; Zager, RA | 1 |
| Bkaily, G; Brochu, I; D'Orléans-Juste, P; Desbiens, L; Gobeil, F; Houde, M; Semaan, W; Simard, E | 1 |
| Lin, L; Liu, Y; Tan, RJ; Zhou, D; Zhou, L | 1 |
| El-Din, MM; El-Mas, MM; Elmallah, AI; Khedr, MM; Nasser, SA; Sabra, R | 1 |
| Jeon, Y; Jin, C; Kleven, DT; Pollock, DM; Pollock, JS; White, JJ | 1 |
| Liu, KD | 1 |
| Kang, JJ; Kang, PM; Ke, Q; Kim, UK; Samad, MA | 1 |
| Coelho, SC; Fraulob-Aquino, JC; Huo, KG; Offermanns, S; Paradis, P; Rautureau, Y; Rehman, A; Schiffrin, EL | 1 |
| Harris, A; Kyle, PB; Morris, R; Owens, MY; Spencer, SK; Wallace, K; Williams, JM | 1 |
| Kang, WL; Xu, GS | 1 |
| Nakano, D; Pollock, DM | 1 |
| Bolenz, C; Bremer, C; Eltze, E; Herrmann, E; Hertle, L; Persigehl, T; Tiemann, A; Wülfing, C | 1 |
| Cockrell, K; Dechend, R; Glover, P; LaMarca, B; Martin, JN; Murphy, SR; Parrish, M; Ray, LF; Roberts, L; Ryan, MJ; Wallukat, G; Wenzel, K | 1 |
| Cockrell, K; Granger, JP; LaMarca, BB; Murphy, SR | 1 |
| Bäcker, A; Cervenka, L; Kramer, HJ; Kujal, P; Vaneckova, I; Vernerová, Z | 1 |
| Abdulkadir, SA; Roh, M | 1 |
| Boesen, EI; Pollock, DM; Pollock, JS; Saleh, MA; Savin, VJ | 1 |
| Arany, M; Cockrell, K; George, E; Granger, JP; Lamarca, B; Martin, JN; Speed, J; Tam Tam, KB | 1 |
| Chen, CC; Hsu, YJ; Lee, TM | 1 |
| Coucha, M; Ergul, A; Li, W | 1 |
| Certíková Chábová, V; Červenka, L; Husková, Z; Kramer, HJ; Kujal, P; Skaroupková, P; Tesař, V; Vaněčková, I; Vaňourková, Z; Vernerová, Z | 1 |
| Fukumoto, T; Kitada, K; Matsumura, Y; Ohkita, M; Okamura, T; Tawa, M; Yamashita, N | 1 |
| Kimura, K; Koyama, M; Matsumura, Y; Ohkita, M | 1 |
| Guimarães, CL; Rae, GA; Trentin, PG | 1 |
| Garber, K | 1 |
| Berthelot, A; Berthon, N; Fellmann, D; Laurant, P | 1 |
| Albertini, M; Clement, MG; Hussain, SN | 1 |
| Chen, AF; Fink, GD; Hesslinger, C; Kapatos, G; Kovesdi, I; Lookingland, KJ; Yang, XQ; Zheng, JS | 1 |
| Henriques, Md; Rae, GA; Sampaio, AL | 1 |
| Ghilardi, JR; Lindsay, TH; Luger, NM; Mantyh, PW; Peters, CM; Pomonis, JD; Sevcik, MA | 1 |
| Akiyoshi, K; Eshiro, K; Hayashi, T; Ieshima, M; Kitaura, Y; Matsumura, Y; Mori, T; Nishida, M; Okada, Y; Takaoka, M; Yoshikawa, J; Yoshiyama, M | 1 |
| Ayach, B; Battistini, B; Blouin, A; Cernacek, P; Jeng, AY; Opgenorth, T; Tsang, J; Verreault, M; Wessale, J | 1 |
| Abassi, Z; Francis, B; Hoffman, A; Karram, T; Winaver, J | 1 |
| Dabbs Loomis, E; Elmarakby, AA; Pollock, DM; Pollock, JS | 1 |
| Allan, A; Brown, L; Fenning, A; Hoey, A; Levick, S | 1 |
| Chichorro, JG; Rae, GA; Souza, GE; Zampronio, AR | 1 |
| Bäcker, A; Cervenka, L; Dvorák, P; Eis, V; Kramer, HJ; Opocenský, M; Schejbalová, S; Vanecková, I; Vernerová, Z | 1 |
| Feng, KT; Guo, X; Hong, MH; Liang, WJ; Mai, HQ; Mo, HY; Ye, YL; Zeng, ZY; Zhang, CQ | 1 |
| Chade, AR; Krier, JD; Lerman, A; Lerman, LO; Textor, SC | 1 |
| Fink, G; Lau, Y; Li, M; Osborn, J; Watts, S | 1 |
| Demirakca, S; Dieckmann, R; Gebhard, MM; Gorenflo, M; Hagl, S; Herpel, E; Klimpel, H; Neumayer, S; Ullmann, MV | 1 |
| Chang, NC; Chen, CC; Lee, TM; Lin, MS | 1 |
| Elgebaly, MM; Ergul, A; Harris, AK; Li, W; Sachidanandam, K | 1 |
| Elgebaly, MM; Ergul, A; Harris, AK; Hutchinson, JR; Mezzetti, EM; Portik-Dobos, V; Sachidanandam, K | 1 |
| Polakowski, JS; Pollock, DM | 1 |
| Opgenorth, TJ; Polakowski, JS; Pollock, DM; Wegner, CD | 1 |
| Intengan, HD; Schiffrin, EL | 1 |
| Best, PJ; Hasdai, D; Holmes, DR; Lerman, A; McKenna, CJ | 1 |
| Chen, YF; Oparil, S | 1 |
| Derebail, VK; Pollock, DM; Pollock, JS; Yamamoto, T | 1 |
3 review(s) available for atrasentan and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic strategies for clinical trials targeting renal recovery.
Topics: Acute Kidney Injury; Animals; Atrasentan; Biomarkers; Caloric Restriction; Clinical Trials as Topic; Disease Models, Animal; Fibrosis; Follow-Up Studies; Humans; Inflammation; Kidney; Kidney Function Tests; Mesenchymal Stem Cell Transplantation; Meta-Analysis as Topic; Pyrrolidines; Recovery of Function; Regeneration; Renal Insufficiency, Chronic; Renal Replacement Therapy; Respiratory Distress Syndrome; Risk Factors; Treatment Outcome | 2014 |
End-organ damage in hypertensive transgenic Ren-2 rats: influence of early and late endothelin receptor blockade.
Topics: Animals; Antihypertensive Agents; Atrasentan; Blood Pressure; Bosentan; Disease Models, Animal; Disease Progression; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Glomerulosclerosis, Focal Segmental; Heterozygote; Homozygote; Hypertension; Male; Podocytes; Pyrrolidines; Rats; Rats, Transgenic; Receptor, Endothelin A; Receptor, Endothelin B; Renin; Sodium Chloride, Dietary; Sulfonamides; Time Factors | 2009 |
Endothelial dysfunction in the pulmonary vascular bed.
Topics: Animals; Antihypertensive Agents; Atrasentan; Bosentan; Controlled Clinical Trials as Topic; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Endothelium, Vascular; Epoprostenol; Heart Failure; Humans; Hypertension, Pulmonary; Hypoxia; Lung Diseases, Obstructive; Nitric Oxide; Oligopeptides; Peptides, Cyclic; Piperidines; Pulmonary Circulation; Pyrrolidines; Receptors, Endothelin; RNA, Messenger; Sulfonamides; Time Factors; Vasoconstriction; Vasodilation | 2000 |
52 other study(ies) available for atrasentan and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Modulation by antenatal therapies of cardiovascular and renal programming in male and female offspring of preeclamptic rats.
Topics: Animals; Atrasentan; Cardiovascular Diseases; Disease Models, Animal; Endothelin A Receptor Antagonists; Female; Kidney Diseases; Male; Methyldopa; Naphthalenes; NG-Nitroarginine Methyl Ester; Pre-Eclampsia; Pregnancy; Prenatal Care; Propionates; Rats; Receptors, Thromboxane A2, Prostaglandin H2; Sex Factors; Sympatholytics | 2021 |
Effects of systemic and renal intramedullary endothelin-1 receptor blockade on tissue NO and intrarenal hemodynamics in normotensive and hypertensive rats.
Topics: Animals; Antihypertensive Agents; Atrasentan; Blood Pressure; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Hemodynamics; Hypertension; Kidney; Nitric Oxide; Oligopeptides; Piperidines; Rats, Inbred SHR; Rats, Sprague-Dawley; Receptor, Endothelin A; Renal Elimination | 2021 |
Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Losartan; Mice; Phosphorylation; Podocytes; Proteinuria; Renin-Angiotensin System; Ribosomal Protein S6 Kinases; TOR Serine-Threonine Kinases | 2020 |
Dysregulation of the Fas/FasL system in an experimental animal model of HELLP syndrome.
Topics: Animals; Atrasentan; Disease Models, Animal; Endoglin; Endothelin A Receptor Antagonists; Fas Ligand Protein; fas Receptor; Female; Gene Expression Regulation; HELLP Syndrome; Liver; Placenta; Pregnancy; Pyrrolidines; Rats, Sprague-Dawley; RNA, Messenger; Time Factors; Vascular Endothelial Growth Factor Receptor-1 | 2017 |
Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury.
Topics: Animals; Atrasentan; Disease Models, Animal; Disease Progression; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Kidney Failure, Chronic; Male; Mice; Mice, Inbred Strains; Oligopeptides; Piperidines; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Renal Insufficiency, Chronic; Reperfusion Injury; RNA, Messenger | 2013 |
High salt-induced hypertension in B2 knockout mice is corrected by the ETA antagonist, A127722.
Topics: Animals; Antihypertensive Agents; Arterial Pressure; Atrasentan; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin-1; Female; Hypertension; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; NG-Nitroarginine Methyl Ester; Peptides, Cyclic; Pyrrolidines; Receptor, Bradykinin B2; Sodium; Sodium Chloride, Dietary; Telemetry | 2013 |
Endothelin receptor a blockade is an ineffective treatment for adriamycin nephropathy.
Topics: Animals; Atrasentan; Disease Models, Animal; Doxorubicin; Endothelin A Receptor Antagonists; Fibrosis; Gene Expression; Kidney Diseases; Kidney Glomerulus; Male; Mice; Podocytes; Proteinuria; Pyrrolidines; Receptor, Endothelin A | 2013 |
Blockade of endothelin ET(A), but not thromboxane, receptors offsets the cyclosporine-evoked hypertension and interrelated baroreflex and vascular dysfunctions.
Topics: Animals; Atrasentan; Blood Pressure; Cyclosporine; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Heart Rate; Hypertension; Male; Naphthalenes; Nitric Oxide; Nitric Oxide Synthase Type III; Propionates; Pyrrolidines; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptors, Thromboxane; Signal Transduction; Time Factors; Vasodilation; Vasodilator Agents | 2014 |
Combined endothelin a blockade and chlorthalidone treatment in a rat model of metabolic syndrome.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antihypertensive Agents; Arterial Pressure; Atrasentan; Cell Adhesion Molecules; Chlorthalidone; Deoxyguanosine; Disease Models, Animal; Diuretics; Drug Combinations; Endothelin A Receptor Antagonists; Endothelins; Hypertension; Inflammation; Kidney Diseases; Male; Membrane Proteins; Metabolic Syndrome; Oxidative Stress; Proteinuria; Pyrrolidines; Rats; Rats, Inbred Dahl; Rats, Sprague-Dawley; Receptor, Endothelin A; Sodium Chloride, Dietary | 2014 |
Endothelin A receptor antagonist, atrasentan, attenuates renal and cardiac dysfunction in Dahl salt-hypertensive rats in a blood pressure independent manner.
Topics: Animals; Atrasentan; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Disease Models, Animal; Echocardiography; Endothelin A Receptor Antagonists; Gene Expression; Heart Diseases; Hemodynamics; Hypertension; Hypertrophy; Kidney Function Tests; Male; Myocytes, Cardiac; Phenylephrine; Pyrrolidines; Rats; Receptor, Endothelin A; Renal Insufficiency, Chronic | 2015 |
Inducible human endothelin-1 overexpression in endothelium raises blood pressure via endothelin type A receptors.
Topics: Animals; Atrasentan; Blood Pressure; Disease Models, Animal; Endothelin-1; Endothelium, Vascular; Humans; Hypertension; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Tamoxifen; Up-Regulation | 2015 |
Hypertension in an Animal Model of HELLP Syndrome is Associated With Activation of Endothelin 1.
Topics: Animals; Atrasentan; Disease Models, Animal; Endoglin; Endothelin-1; Female; HELLP Syndrome; Hypertension; Placenta; Pregnancy; Pyrrolidines; Rats; Vascular Endothelial Growth Factor Receptor-1 | 2016 |
Atrasentan increased the expression of klotho by mediating miR-199b-5p and prevented renal tubular injury in diabetic nephropathy.
Topics: 3' Untranslated Regions; Albuminuria; Animals; Antioxidants; Atrasentan; Biomarkers; Cell Line; Diabetic Nephropathies; Disease Models, Animal; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation; Glucuronidase; Humans; Kidney Function Tests; Kidney Tubules; Klotho Proteins; Male; Mice; MicroRNAs; Middle Aged; Mitochondria; Promoter Regions, Genetic; Pyrrolidines; RNA Interference | 2016 |
Contribution of endothelin A receptors in endothelin 1-dependent natriuresis in female rats.
Topics: Animals; Atrasentan; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin-1; Female; Hypertension; Kidney Medulla; Male; Natriuresis; Pyrrolidines; Rats; Rats, Inbred WKY; Rats, Mutant Strains; Receptor, Endothelin A; Receptor, Endothelin B; Regional Blood Flow; Sex Characteristics; Sodium | 2009 |
Endothelin-A-receptor antagonism with atrasentan exhibits limited activity on the KU-19-19 bladder cancer cell line in a mouse model.
Topics: Animals; Atrasentan; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Female; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Mitosis; Necrosis; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thymus Gland; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2009 |
Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1.
Topics: Animals; Atrasentan; Autoantibodies; Blood Pressure; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin-1; Female; Hypertension; Kidney; Placenta; Pre-Eclampsia; Pregnancy; Pregnancy, Animal; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1 | 2009 |
Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats.
Topics: Analysis of Variance; Animals; Atrasentan; Blood Pressure Determination; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Female; Hypertension, Pregnancy-Induced; Pre-Eclampsia; Pregnancy; Pregnancy Proteins; Pregnancy, Animal; Probability; Pyrrolidines; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Fibroblast Growth Factor, Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Vascular Endothelial Growth Factor Receptor-1 | 2010 |
Targeting the endothelin receptor in prostate cancer bone metastasis: Back to the mouse?
Topics: Animals; Atrasentan; Bone Neoplasms; Disease Models, Animal; Endothelin Receptor Antagonists; Humans; Male; Mice; Molecular Targeted Therapy; Prostatic Neoplasms; Pyrrolidines | 2010 |
Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes.
Topics: Animals; Atrasentan; Diabetes Mellitus, Experimental; Disease Models, Animal; Endothelin A Receptor Antagonists; Immunoassay; Kidney Glomerulus; Male; Membrane Proteins; Oligopeptides; Piperidines; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A | 2011 |
Endothelin type A receptor antagonist attenuates placental ischemia-induced hypertension and uterine vascular resistance.
Topics: Animals; Atrasentan; Blood Flow Velocity; Blood Pressure; Disease Models, Animal; Endothelin Receptor Antagonists; Female; Hypertension; Ischemia; Placenta; Pregnancy; Pyrrolidines; Rats; Rats, Sprague-Dawley; Ultrasonography; Uterine Artery; Vascular Resistance | 2011 |
Impact of elevated uric acid on ventricular remodeling in infarcted rats with experimental hyperuricemia.
Topics: Allopurinol; Analysis of Variance; Animals; Antioxidants; Atrasentan; Biomarkers; Cyclic N-Oxides; Dinoprost; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin-1; Fibrosis; Gout Suppressants; Hypertrophy, Left Ventricular; Hyperuricemia; Isoprostanes; Male; Myocardial Infarction; Myocardium; Oxidative Stress; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; RNA, Messenger; Spin Labels; Superoxides; Time Factors; Up-Regulation; Uric Acid; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling; Xanthine Oxidase | 2011 |
The effect of endothelin receptor A antagonism on basilar artery endothelium-dependent relaxation after ischemic stroke.
Topics: Acetylcholine; Animals; Atrasentan; Basilar Artery; Brain Ischemia; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Male; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Reperfusion Injury; Stroke; Vasodilation | 2012 |
Effects of combined endothelin A receptor and renin-angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrasentan; Disease Models, Animal; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Hypertension, Renal; Indoles; Kidney; Losartan; Male; Nephrectomy; Pyrrolidines; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptor, Angiotensin, Type 1; Receptor, Endothelin A; Renal Insufficiency, Chronic; Renin-Angiotensin System; Survival Analysis; Treatment Outcome | 2012 |
Different effects of AT1 receptor antagonist and ET(A) receptor antagonist on ischemia-induced norepinephrine release in rat hearts.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrasentan; Benzimidazoles; Biphenyl Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Norepinephrine; Pyrrolidines; Rats; Rats, Sprague-Dawley; Tetrazoles; Time Factors | 2012 |
Reduced NO production rapidly aggravates renal function through the NF-κB/ET-1/ETA receptor pathway in DOCA-salt-induced hypertensive rats.
Topics: Animals; Atrasentan; Desoxycorticosterone; Disease Models, Animal; Disease Susceptibility; Endothelin-1; Hypertension; Kidney Diseases; Male; NF-kappa B; Nitric Oxide; Nitroarginine; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Severity of Illness Index; Sodium Chloride, Dietary; Thiocarbamates | 2012 |
Endothelin ET(B) receptor-mediated mechanisms involved in oleic acid-induced acute lung injury in mice.
Topics: Acute Disease; Analysis of Variance; Animals; Atrasentan; Bosentan; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Evans Blue; Lung; Male; Mice; Mice, Inbred Strains; Neutrophil Infiltration; Oleic Acid; Pyrimidines; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Respiratory Distress Syndrome; Sulfonamides | 2002 |
Why it hurts: researchers seek mechanisms of cancer pain.
Topics: Acidosis; Analgesics; Animals; Antineoplastic Agents; Atrasentan; Bone Neoplasms; Diphosphonates; Disease Models, Animal; Glycoproteins; Humans; Ion Channels; Neoplasms; Osteoprotegerin; Pain; Pyrrolidines; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor | 2003 |
Effect of magnesium on mRNA expression and production of endothelin-1 in DOCA-salt hypertensive rats.
Topics: Animals; Aorta; Atrasentan; Blood Pressure; Desoxycorticosterone; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Heart Rate; Heart Ventricles; Hypertension; Kidney; Magnesium Oxide; Male; Organ Size; Pyrrolidines; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2003 |
Role of endothelin ETA receptors in sepsis-induced mortality, vascular leakage, and tissue injury in rats.
Topics: Animals; Atrasentan; Disease Models, Animal; Edema; Endothelin A Receptor Antagonists; Male; Multiple Organ Failure; Pyrrolidines; Rats; Rats, Sprague-Dawley; Sepsis | 2003 |
Gene transfer of human guanosine 5'-triphosphate cyclohydrolase I restores vascular tetrahydrobiopterin level and endothelial function in low renin hypertension.
Topics: Acetophenones; Animals; Antioxidants; Atrasentan; Biopterins; Carotid Arteries; Cyclic N-Oxides; Desoxycorticosterone; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Enzyme Inhibitors; Gene Transfer Techniques; Genetic Therapy; GTP Cyclohydrolase; Humans; Hypertension; In Vitro Techniques; Male; Nitric Oxide; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Sodium Chloride; Spin Labels; Superoxides; Vasodilation | 2003 |
Effects of endothelin ETA receptor antagonism on granulocyte and lymphocyte accumulation in LPS-induced inflammation.
Topics: Animals; Antihypertensive Agents; Atrasentan; Cell Adhesion Molecules; Chemokines; Chemotaxis, Leukocyte; Disease Models, Animal; Endothelin A Receptor Antagonists; Granulocytes; Inflammation; Lipopolysaccharides; Lung; Lymphocytes; Male; Mice; Mice, Inbred BALB C; Peptides, Cyclic; Pleurisy; Pyrrolidines | 2004 |
Endothelin and the tumorigenic component of bone cancer pain.
Topics: Analysis of Variance; Animals; Atrasentan; Behavior, Animal; Bone Neoplasms; Calcitonin Gene-Related Peptide; Disease Models, Animal; Dynorphins; Endothelin Receptor Antagonists; Endothelin-1; Ganglia, Spinal; Gene Expression Regulation, Neoplastic; Glial Fibrillary Acidic Protein; Immunohistochemistry; Male; Mice; Mice, Inbred Strains; Pain; Pain Measurement; Pyrrolidines; Receptors, Endothelin; Sarcoma; Sciatic Nerve; Time Factors | 2004 |
Selective endothelin ET(B) receptor antagonist improves left ventricular function but exaggerates degeneration of cardiomyocytes in J2N-k hamsters.
Topics: Animals; Atrasentan; Cardiomyopathy, Dilated; Cricetinae; Disease Models, Animal; Endothelin B Receptor Antagonists; Heart; Heart Function Tests; Male; Muscle Cells; Myocardium; Pyrrolidines; Ventricular Function, Left | 2005 |
Role of the endothelin system in secondary pulmonary hypertension related to air embolism: lessons learned from testing four classes of endothelin blockers in a rat model.
Topics: Acute Disease; Animals; Aspartic Acid Endopeptidases; Atrasentan; Benzofurans; Cardiovascular Agents; Disease Models, Animal; Embolism, Air; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-Converting Enzymes; Endothelins; Hemodynamics; Hypertension, Pulmonary; Male; Metalloendopeptidases; Organophosphonates; Protease Inhibitors; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Time Factors; Ventricular Dysfunction, Right | 2004 |
Renal and systemic effects of chronic blockade of ET(A) or ET(B) receptors in normal rats and animals with experimental heart failure.
Topics: Animals; Atrasentan; Blood Pressure; Cardiomegaly; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Heart Failure; Hemodynamics; Infusion Pumps, Implantable; Kidney; Male; Natriuresis; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Time Factors; Vasoconstriction; Vasodilation | 2004 |
ETA receptor blockade attenuates hypertension and decreases reactive oxygen species in ETB receptor-deficient rats.
Topics: Animals; Animals, Genetically Modified; Antihypertensive Agents; Aorta; Atrasentan; Blood Pressure; Dinoprost; Disease Models, Animal; Down-Regulation; Endothelin A Receptor Antagonists; Endothelins; Hypertension; Male; Pyrrolidines; Rats; Receptor, Endothelin A; Receptor, Endothelin B; Sodium Chloride, Dietary; Superoxides; Time Factors | 2004 |
Reversal of cardiac dysfunction by selective ET-A receptor antagonism.
Topics: Acetylcholine; Action Potentials; Animals; Aorta, Thoracic; Atrasentan; Body Weight; Collagen; Desoxycorticosterone; Disease Models, Animal; Drinking; Endothelin A Receptor Antagonists; Hypertension; Hypertrophy, Left Ventricular; In Vitro Techniques; Male; Myocardial Contraction; Nephrectomy; Norepinephrine; Papillary Muscles; Potassium Chloride; Pyrrolidines; Rats; Rats, Wistar; Ventricular Remodeling | 2005 |
Orofacial cold hyperalgesia due to infraorbital nerve constriction injury in rats: reversal by endothelin receptor antagonists but not non-steroidal anti-inflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Atrasentan; Bosentan; Carrageenan; Celecoxib; Cold Temperature; Dexamethasone; Disease Models, Animal; Drug Evaluation, Preclinical; Endothelin-1; Endothelins; Grooming; Hyperalgesia; Indomethacin; Male; Maxillary Nerve; Nerve Compression Syndromes; Oligopeptides; Peptide Fragments; Peptides, Cyclic; Piperidines; Pyrazoles; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Trigeminal Neuralgia | 2006 |
Early-onset endothelin receptor blockade in hypertensive heterozygous Ren-2 rats.
Topics: Animals; Animals, Genetically Modified; Antihypertensive Agents; Atrasentan; Blood Pressure; Body Weight; Bosentan; Cardiomegaly; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin Receptor Antagonists; Endothelin-1; Glomerulosclerosis, Focal Segmental; Heterozygote; Hypertension; Male; Proteinuria; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Endothelin; Renin; Sodium Chloride, Dietary; Sulfonamides; Time Factors | 2006 |
Therapeutic targeting of the endothelin a receptor in human nasopharyngeal carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Atrasentan; Cell Proliferation; Cisplatin; Disease Models, Animal; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Fluorouracil; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Neoplasms; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |
Endothelin-a receptor blockade improves renal microvascular architecture and function in experimental hypercholesterolemia.
Topics: Animals; Atrasentan; Blood Pressure; Disease Models, Animal; Endothelin A Receptor Antagonists; Glomerular Filtration Rate; Hypercholesterolemia; Imaging, Three-Dimensional; Kidney; Microcirculation; Pyrrolidines; Receptor, Angiotensin, Type 1; Renin; Sus scrofa; Tomography, X-Ray Computed; Vascular Endothelial Growth Factor A | 2006 |
Chronic activation of endothelin B receptors: new model of experimental hypertension.
Topics: Animals; Atrasentan; Blood Pressure; Blood Volume; Cardiac Output; Disease Models, Animal; Diuresis; Drug Administration Schedule; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Heart Rate; Hypertension; Male; Natriuresis; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin B; Stroke Volume; Sulfonamides; Vascular Resistance; Viper Venoms | 2007 |
Atrasentan treatment of pulmonary vascular disease in piglets with increased pulmonary blood flow.
Topics: Animals; Atrasentan; Blood Pressure; Cardiac Output; Chronic Disease; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin-1; Gene Expression Regulation; Hypertension, Pulmonary; Hypertrophy; Immunohistochemistry; Lung; Pulmonary Artery; Pulmonary Circulation; Pyrrolidines; Random Allocation; Receptor, Endothelin B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Swine; Vascular Endothelial Growth Factor A | 2007 |
Effect of endothelin receptor antagonists on ventricular susceptibility in postinfarcted rats.
Topics: Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Atrasentan; Blotting, Western; Bosentan; Cardiac Pacing, Artificial; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; GAP-43 Protein; Hemodynamics; Hydralazine; Immunohistochemistry; Male; Methoxyhydroxyphenylglycol; Myocardial Infarction; Myocardium; Nerve Growth Factor; Neurofilament Proteins; Norepinephrine; Polymerase Chain Reaction; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; RNA, Messenger; Sulfonamides; Sympathetic Nervous System; Time Factors; Tyrosine 3-Monooxygenase; Up-Regulation | 2008 |
Effect of chronic endothelin receptor antagonism on cerebrovascular function in type 2 diabetes.
Topics: Acetylcholine; Animals; Atrasentan; Basilar Artery; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Male; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents; Viper Venoms | 2008 |
Effect of chronic and selective endothelin receptor antagonism on microvascular function in type 2 diabetes.
Topics: Acetylcholine; Animals; Atrasentan; Cardiovascular Agents; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Male; Mesenteric Arteries; Microcirculation; Myography; Peptides, Cyclic; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Up-Regulation; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents; Viper Venoms | 2008 |
ETA receptor blockade prevents hypertension associated with exogenous endothelin-1 but not renal mass reduction in the rat.
Topics: Administration, Oral; Animals; Atrasentan; Blood Pressure; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Hypertension, Renal; Kidney; Kidney Failure, Chronic; Male; Nephrectomy; Protein Precursors; Proteinuria; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A | 1997 |
Beneficial effect of ETA receptor blockade in a rat model of radiocontrast-induced nephropathy.
Topics: Acute Kidney Injury; Animals; Atrasentan; Contrast Media; Creatinine; Diatrizoate; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelins; Indomethacin; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Prostaglandin Antagonists; Proteinuria; Pyrrolidines; Rats; Rats, Sprague-Dawley; Stereoisomerism | 1997 |
Mechanical properties of mesenteric resistance arteries from Dahl salt-resistant and salt-sensitive rats: role of endothelin-1.
Topics: Animals; Atrasentan; Biomechanical Phenomena; Blood Pressure; Disease Models, Animal; Elasticity; Endothelin Receptor Antagonists; Endothelin-1; Hypertension; In Vitro Techniques; Male; Mesenteric Arteries; Pyrrolidines; Rats; Receptor, Endothelin A; Sodium Chloride; Vascular Resistance | 1998 |
Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia.
Topics: Administration, Oral; Animals; Atrasentan; Bosentan; Coronary Vessels; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelium, Vascular; Hemodynamics; Hypercholesterolemia; Pyrrolidines; Random Allocation; Receptor, Endothelin A; Sulfonamides; Swine | 1999 |
Combined effects of AT(1) and ET(A) receptor antagonists, candesartan, and A-127722 in DOCA-salt hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atrasentan; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body Weight; Desoxycorticosterone; Disease Models, Animal; Drug Therapy, Combination; Endothelin Receptor Antagonists; Endothelin-1; Hypertension; Kidney; Male; Natriuresis; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles | 2000 |